SCHEMBL17789063

SCHEMBL17789063

COc1c(CNC(=O)C(C)(C)C)c(C(F)(F)F)nn1C

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MEN1 O00255 4/20 0.36
▸ KMT2A Q03164 4/20 0.36
▸ CYP1A2 P05177 4/20 0.35
▸ CYP2C19 P33261 4/20 0.35
▸ CYP2C9 P11712 3/20 0.35
▸ MAPT P10636 3/20 0.34
▸ GAA P10253 2/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ CACNA1B Q00975 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17792577 0.86 ALDH1A1 (0.39) NPC1PKMALDH1A1KDM4EMEN1
SCHEMBL18743922 0.84 NPC1 (0.34) NPC1PKMALDH1A1KDM4EMEN1
SCHEMBL17789058 0.82 SHMT2 (0.40) NPC1ALDH1A1KDM4EKMT2AMAPT
SCHEMBL537606 0.75 SMN1; SMN2 (0.37) NPC1PKMALDH1A1KDM4EMEN1
SCHEMBL17789066 0.75 DRD4 (0.37) MAPT
SCHEMBL16402671 0.72 ALDH1A1 (0.35) NPC1PKMALDH1A1KDM4EMEN1
SCHEMBL17789047 0.71 SHMT2 (0.40) NPC1ALDH1A1KDM4EKMT2ACYP2C19
SCHEMBL18744320 0.71 RIPK1 (0.40) NPC1ALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL19390907 0.70 EZH2 (0.39) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL25587412 0.70 MAPT (0.37) ALDH1A1KDM4EMAPTSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200361914-A1 SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS Epizyme, Inc. 2020-11-19 — — US disclosed
US-20180065954-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS Epizyme, Inc. 2018-03-08 — — US disclosed
US-20170217941-A1 SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS Epizyme, Inc. 2017-08-03 — — US disclosed
US-20170217941-A1 SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS Epizyme, Inc. 2017-08-03 — — US disclosed
US-9624205-B2 Substituted 6,5-fused bicyclic heteroaryl compounds Epizyme, Inc. (US) 2017-04-18 — — US disclosed
US-9624205-B2 Substituted 6,5-fused bicyclic heteroaryl compounds Epizyme, Inc. (US) 2017-04-18 — — US disclosed
US-20160152604-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS Epizyme, Inc. 2016-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152604-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A5, PAICS NPC1 57/4885PKM 2466/4885ALDH1A1 552/4885
US-20180065954-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A5, PAICS NPC1 57/4885PKM 2466/4885ALDH1A1 552/4885
US-20170217941-A1 SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS BCOR, CYP2B6, AHR NPC1 953/4885PKM 3247/4885ALDH1A1 737/4885
US-20200361914-A1 SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS BCOR, CYP2B6, AHR NPC1 953/4885PKM 3247/4885ALDH1A1 737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback